Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Common Equity (2018 - 2025)

BioNexus Gene Lab's Common Equity history spans 8 years, with the latest figure at $6.8 million for Q3 2025.

  • For Q3 2025, Common Equity fell 27.4% year-over-year to $6.8 million; the TTM value through Sep 2025 reached $6.8 million, down 27.4%, while the annual FY2024 figure was $8.3 million, 13.82% down from the prior year.
  • Common Equity for Q3 2025 was $6.8 million at BioNexus Gene Lab, down from $7.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $9.7 million in Q4 2023 and bottomed at $5.6 million in Q2 2023.
  • The 5-year median for Common Equity is $7.1 million (2022), against an average of $7.6 million.
  • The largest annual shift saw Common Equity soared 70.7% in 2024 before it dropped 27.4% in 2025.
  • A 5-year view of Common Equity shows it stood at $7.2 million in 2021, then dropped by 7.17% to $6.7 million in 2022, then skyrocketed by 44.9% to $9.7 million in 2023, then fell by 13.82% to $8.3 million in 2024, then fell by 18.1% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Common Equity are $6.8 million (Q3 2025), $7.5 million (Q2 2025), and $7.8 million (Q1 2025).